The possible mechanism of resistance to anti-angiogenic therapy can be bevacizumab-induced reduction of MIF expression in cancer cells resulting in the expansion of M2 macrophages, which in turn promotes tumor growth [232]. The gene discussed is MIF; the disease is neoplasm.